RBCC: Could Stem Cells Be Key to Promising Autism Therapy?

Before you go, we thought you'd like these...
Before you go close icon

RBCC: Could Stem Cells Be Key to Promising Autism Therapy?

NOKOMIS, Fla.--(BUSINESS WIRE)-- Rainbow Coral Corp. (OTCBB: RBCC) subsidiary Rainbow BioSciences will keep a close eye on a new study that could potentially lead to stem cell therapies for children with autism.

Researchers have been given the go-ahead by the FDA to launch a small study evaluating the effectiveness of autism treatments using patients' own umbilical cord blood. Thirty children, aged two to seven, will receive injections of their own stem cells from the cord blood banked by their parents at birth.


Scientists will evaluate whether the stem cell therapy helps improve language and behavior in the children. Although the cause of autism is unknown and there is no cure for the disorder, one theory suggests that autism occurs because cell in the brain, known as neurons, are not connecting normally. It's possible that stem cells may address this problem.

RBCC is working to capitalize on the rising demand for effective new stem cell treatments by bringing a potentially game-changing stem cell technology to market. The company is close to a deal with Regenetech to acquire a license to perform cell expansion using that company's Rotary Cell Culture SystemTM, a rotating-wall bioreactor originally developed by NASA.

"The rotating-wall bioreactor is capable of multiplying functional, 3-D stem cells for use in a variety of research projects," said RBCC CEO Patrick Brown. "Stem cells carry tremendous potential to help researchers develop new treatments and cures for devastating diseases from Parkinson's to Alzheimer's and even autism, but much research must be done first. Consequently, we're very optimistic about the market potential for this revolutionary bioreactor technology."

RBCC plans to offer the new technology to help kickstart billions of dollars' worth of research in an industry currently dominated by Amgen, Inc. (NAS: AMGN) , Celgene Corporation (NAS: CELG) , Genzyme Corp. (NAS: GENZ) and Gilead Sciences Inc. (NAS: GILD) .

For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com

KEYWORDS:   United States  North America  Florida

INDUSTRY KEYWORDS:

The article RBCC: Could Stem Cells Be Key to Promising Autism Therapy? originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners